Replimune Group, Inc.
REPL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for REPL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · REPL
Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies, with a lead product candidate RP1 (vusolimogene oderparepvec) targeting advanced melanoma and other skin cancers.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 23 clinical trials · 3 catalysts for Replimune Group, Inc..
Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies, with a lead product candidate RP1 (vusolimogene oderparepvec) targeting advanced melanoma and other skin cancers.
- Cash and cash equivalents and short-term investments were $195.3 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
- Net loss for the quarter ended June 30, 2026 was $69.8 million, with shareholders' equity of $166.2 million and total debt of $21.7 million [sec].
- The company expects its cash runway to fund operations for greater than twelve months from June 30, 2026, including commercialization of TUDRIQEV in advanced melanoma [sec_mda · as of 2026-08-14].
- Replimune is advancing clinical trials for RP1, RP2, and RP3, and is scaling up its in-house manufacturing facility [sec_mda · as of 2026-06-29].
- The company has multiple Phase 3 catalyst readouts expected in 2030 and 2031 for RP1 in combination with nivolumab [catalyst_timeline].
What works
- Cash position of $195.3 million as of June 30, 2026 provides a runway of over twelve months, supporting ongoing trials and near-term commercialization [sec_mda · as of 2026-08-14].
- The company has a proprietary RPx platform for oncolytic immunotherapy, with multiple product candidates (RP1, RP2, RP3) in clinical development [sec_mda · as of 2026-06-29].
- Replimune is preparing for the potential commercialization of RP1 (TUDRIQEV) in skin cancers, indicating progress toward a revenue-generating product [sec_mda · as of 2026-08-14].
What to weigh
- The company is not yet profitable and expects expenses to increase substantially as it advances clinical trials and commercialization, with no guarantee of achieving profitability [sec_mda · as of 2026-08-14].
- Cash burn is significant, with a net loss of $69.8 million in the latest quarter and cash declining from $268.9 million (March 31, 2026) to $195.3 million (June 30, 2026) [sec_mda · as of 2026-06-29][sec_mda · as of 2026-08-14].
- The company faces numerous risks typical of pharmaceutical development, including uncertain clinical trial outcomes, regulatory hurdles, and the need for additional financing [sec_mda · as of 2026-06-29].
From the filings
Quoted directly from source documents.
Cash position and runway as of June 30, 2026
“As of June 30, 2026, we had cash and cash equivalents and short-term investments of $195.3 million. Based on its current operating plan, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to fund its operations for greater than twelve months from the issuance of these condensed consolidated financial statements”
SEC MD&A · August 14, 2026
Clinical-stage focus and pipeline
“We are a clinical-stage biotechnology company committed to applying our leading expertise in the field o”
SEC MD&A · June 29, 2026
Risk of not achieving profitability
“Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2030-11-12 · Phase3_Topline — Phase 3 Topline: Phase 3 Study to Evaluate the Safety and Efficacy of AAV5-hRKp.RPGR for the Treatment of Japanese X- — Topline data from a Phase 3 study evaluating RP1 in combination with nivolumab for a specific patient population.
- 2031-03-31 · Phase3_Topline · nivolumab — Phase 3 Topline: Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs — Topline results from a randomized Phase 3 study comparing RP1 plus nivolumab versus a comparator.
- 2031-10-01 · Phase3_Topline · nivolumab — Phase 3 Topline: A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combinati — Topline data from a Phase 2/3 study evaluating RP2 in combination with nivolumab.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Phase 3 trials for RP1 in combination with nivolumab are ongoing; failure could impair pipeline value [sec_mda · as of 2026-06-29].
- Cash burn and financing need — Net loss of $69.8M in Q1 FY2027; cash declined $73.6M in three months; additional capital likely needed [sec_mda · as of 2026-08-14].
- Commercialization uncertainty — Even if approved, product sales may not lead to profitability; commercialization costs are substantial [sec_mda · as of 2026-08-14].
- Manufacturing scale-up challenges — In-house manufacturing facility not yet fully validated; reliance on third-party manufacturers for clinical supply [sec_mda · as of 2026-06-29].
What to watch
- Phase 3 topline data for RP1 in combination with nivolumab, expected in 2030 and 2031 [catalyst_timeline].
- Cash burn rate and any future financing rounds, given the decline from $268.9M to $195.3M in three months [sec_mda · as of 2026-08-14].
- Progress of the in-house manufacturing facility validation and its impact on clinical supply [sec_mda · as of 2026-06-29].
- Regulatory updates and potential approval decisions for RP1 (TUDRIQEV) in advanced melanoma [sec_mda · as of 2026-08-14].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Replimune Group, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Replimune Group, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
7.8 months
D/E 1.39 · 0% dilution
Lead: Phase 3
3 candidates
3 upcoming, next in ~1535d
2 buys · 12 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
187
Total value held
$633.7M
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 11,045,336 | $84.5M |
| rtw investments, lp | 7,356,916 | $56.3M |
| blackrock, inc. | 6,239,239 | $47.7M |
| vanguard capital management llc | 5,518,240 | $42.2M |
| suvretta capital management, llc | 4,221,836 | $32.3M |
| state street corp | 3,782,237 | $28.9M |
| fcpm iii services b.v. | 2,808,368 | $21.5M |
| d. e. shaw & co., inc. | 2,336,528 | $17.9M |
| susquehanna international group, llp | 2,320,879 | $17.8M |
| goldman sachs group inc | 2,277,276 | $17.4M |
Showing top 10 of 187 institutional holders of Replimune Group, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 35.5%
- Days to cover
- 10.2
- Shares short
- 16,335,211
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
REPL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Replimune Group, Inc.?
Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies, with a lead product candidate RP1 (vusolimogene oderparepvec) targeting advanced melanoma and other skin cancers.
What is Replimune Group, Inc.'s lead drug candidate?
Replimune Group, Inc.'s most advanced tracked candidate is rp1 (Phase 2) for Advanced Melanoma; Cutaneous Squamous Cell Carcinoma.
What is Replimune Group, Inc.'s next catalyst?
Replimune Group, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Phase 3 Study to Evaluate the Safety and Efficacy of AAV5-hRKp.RPGR for the Treatment of Japanese X-" — expected November 12, 2030.
Who is the CEO of Replimune Group, Inc.?
Dr. Sushil Patel Ph.D. is the chief executive officer of Replimune Group, Inc. (REPL).
Where is Replimune Group, Inc. headquartered?
Replimune Group, Inc. (REPL) is headquartered in Woburn, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.